Loading
Mckesson Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Feb 2016.
Mckesson Corp: what insiders have been doing
Mckesson Corp, classified in the Healthcare & Pharma sector, is a listed company based in Irving, United States, founded in 1833. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 27 filings signed by 14 insiders.
No insider bought on the market over the period, while 6 insiders filed 9 sales totalling €4.0M. At €2.3M, the sale published on 4 March 2026 by Lau Michele is the largest of the period.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 27 filings here. The full history, which starts in 2016, counts 1 purchase against 86 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 March 2026 lists revenue at 403.43 bn USD and net income at 4.76 bn USD; the dividend was 3.17 USD per share.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
264
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€136M
86 ops. · all time
Who traded when
BuySaleTyler Brian S.9 sales
Napoleon B. Rutledge Jr.8 sales
LeAnn B. Smith6 sales
Michele Lau3 sales
Rodgers Thomas L3 sales
Vitalone Britt J.2 sales
+2 other insiders
Since the insiders bought
- -9.7%Entry US$153.81 · Close at T+365 US$138.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Mckesson Corp Buy (bullish), based on 13 analysts. Average price target: US$986.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,845 of 24,148 companies
41.5
score / 100
Value50
Quality33
FCF yld4.6%
Earn yld4.1%
EV/EBITDA17.4x
ROE·
Gross mgn3.6%
Net mgn1.2%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$998.64
Analyst consensus
13 analystsBuy
US$845.00Target US$986.15(-1%)US$1,070.00
Income statement
RevenueUS$403.4B
Gross profitUS$14.6B4% margin
EBITDAUS$7.2B2% margin
Net incomeUS$4.8B1.1% margin
Valuation
PER (trailing)26.8x
PER (forward)19.7x
Beta0.30
Balance sheet & cash
Market capUS$116.4B
Total debtUS$8.6B
Free Cash FlowUS$5.4B
Profitability & ownership
ROA4.7%
% insiders0.1%
% institutions93.5%
Last declaration on 15 October 2026
Declarations264 total
801 shares@ US$995.1672CommonSEC144:0001959173-26-007388
111 shares@ US$891.450.0001% mcap4.5% of flowCommon StockSEC:0000927653-26-000249:0
301 shares@ US$892.3250.0003% mcap50.0% of flowCommon StockSEC:0000927653-26-000239:0
301 shares@ US$892.32230.0003% mcap50.0% of flowCOMMONSEC144:0001000275-26-000098
7,925 shares@ US$843.3050.0065% mcap17.7% of flowCommonSEC144:0001959173-26-005575
277 shares@ US$814.040.0002% mcap100.0% of flowCommon StockSEC:0000927653-26-000207:0
277 shares@ US$814.040.0002% mcap26.9% of flowCommon StockSEC:0000927653-26-000202:0
277 shares@ US$814.040.0002% mcap100.0% of flowCommon StockSEC:0000927653-26-000205:0
8,463 shares@ US$793.560.0066% mcap4.6% of flowCommonSEC144:0001959173-26-005128
8,463 shares@ US$775.130.0069% mcap4.4% of flowCommonSEC144:0001959173-26-004726
4,929 shares@ US$763.000.0039% mcap2.5% of flowCommonSEC144:0001959173-26-004461
699 shares@ US$735.270.0005% mcap5.2% of flowCommonSEC144:0001959173-26-004235
54 shares@ US$766.080.0000% mcap5.0% of flowCommon StockSEC:0000927653-26-000122:1
136 shares0Common StockSEC:0000927653-26-000122:0
192 shares@ US$761.890.0001% mcap17.6% of flowCommon StockSEC:0000927653-26-000077:1
843 shares@ US$761.890.0006% mcap77.4% of flowCommon StockSEC:0000927653-26-000077:3
788 shares0Common StockSEC:0000927653-26-000077:0
2,339 shares0Common StockSEC:0000927653-26-000077:2
2,725 shares@ US$990.0084.6% of flowCommon StockSEC:0000927653-26-000032:0
349 shares@ US$939.86537.8% of flowCommon StockSEC:0000927653-26-000030:0
190 shares@ US$945.005.9% of flowCommon StockSEC:0000927653-26-000028:0
303 shares@ US$933.398.8% of flowCommon StockSEC:0000927653-26-000025:0
508 shares0Common StockSEC:0000927653-26-000023:0
3,990 shares0Common StockSEC:0000927653-26-000021:0
328 shares@ US$955.0014.1% of flowCommon StockSEC:0000927653-26-000019:0
25 of 264 declarations
About Mckesson Corp
McKesson Corp. (NYSE: MCK) is one of the largest healthcare supply-chain and services companies in the United States, with a business model centered on pharmaceutical distribution, prescription technology solutions, and higher-value specialty healthcare services. Headquartered in Irving, Texas, United States, McKesson sits at a critical point in the healthcare ecosystem, serving pharmacies, hospitals, physician practices, manufacturers, payers, and government-related customers. Founded in 1833, the company has a long operating history and has evolved from a traditional wholesaler into a diversified healthcare infrastructure provider.
McKesson’s core franchise remains large-scale pharmaceutical distribution. The company distributes branded, generic, specialty, biosimilar, and over-the-counter drugs in the U.S. and Canada, while also supplying medical-surgical products and related healthcare goods. Beyond distribution, McKesson offers services designed to improve medication access, affordability, transparency, and adherence. Its capabilities extend into oncology and multispecialty care, which management has highlighted as a strategic growth area due to their higher-margin profile and stronger differentiation versus commodity distribution.
Read moreShow less
The company now reports through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This structure better reflects McKesson’s evolving mix and emphasizes the company’s push toward more focused capital allocation and clearer strategic reporting. The Prescription Technology Solutions platform connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma clients, supporting prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support. In practical terms, McKesson operates as both a logistics powerhouse and a healthcare services enabler.
Competitive positioning is strong because McKesson operates at scale in an industry where distribution density, service reliability, regulatory execution, and customer relationships are essential. The company says it offers more than 285,000 national brand products, alongside its own private-label offerings, through its U.S. distribution network. It also maintains a broad geographic footprint across North America, with distribution centers, pharmacy locations, and business offices in the United States and internationally.
Recent developments have been important for investors. In 2025, McKesson announced a new organizational structure and disclosed its intent to separate the Medical-Surgical Solutions segment. It also moved ahead with the sale of its Norway businesses. More recently, fiscal 2026 results showed continued revenue growth and strong adjusted earnings expansion, supported by specialty product distribution and disciplined execution. For investors on the NYSE, McKesson remains a high-quality U.S. healthcare platform with defensive cash generation and selective growth exposure in specialty care and prescription technology.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
